News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Subscribe To Our Newsletter & Stay Updated
